Advertisement
Screener

ANAPTYSBIO, INC. (ANAB) Executive Pay versus Performance: Pay versus Performance

ANAPTYSBIO, INC. Pay versus Performance

The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.

  • 2025-12-31: PEO Daniel Faga; PEO total compensation $6.13M; PEO compensation actually paid $41.74M; Other NEO average total compensation $2.19M.
  • 2024-12-31: PEO Daniel Faga; PEO total compensation $13.63M; PEO compensation actually paid $9.16M; Other NEO average total compensation $3.91M.
  • 2023-12-31: PEO Daniel Faga; PEO total compensation $7.46M; PEO compensation actually paid -$1.74M; Other NEO average total compensation $2.35M.
  • 2024-12-31: PEO Daniel Faga; PEO total compensation $13.63M; PEO compensation actually paid $9.16M; Other NEO average total compensation $3.91M.
Fiscal year endPEOPEO total compensationPEO compensation actually paidOther NEO average total compensationOther NEO average compensation actually paidTotal shareholder returnPeer group total shareholder returnNet incomeCompany-selected measureProxy filed
2025-12-31Daniel Faga$6.13M$41.74M$2.19M$12.47M$156.00-$13.23M2026-06-29
2024-12-31Daniel Faga$13.63M$9.16M$3.91M$1.84M$43.00-$145.23M2026-06-29
2023-12-31Daniel Faga$7.46M-$1.74M$2.35M$544.25K$69.00-$163.62M2026-06-29
2024-12-31Daniel Faga$13.63M$9.16M$3.91M$1.84M$38.00-$145.23M2025-04-29
2023-12-31Daniel Faga$7.46M-$1.74M$2.35M$544.25K$62.00-$163.62M2025-04-29
2022-12-31$3.83M$2.23M$89.00-$128.72M2025-04-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Innoviva, Inc. (INVA)United States$1.493B4.62
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74